Aza- indolyl derivatives for treating obesity
AssigneesHoffman-La Roche Inc., Vernalis Research Limited
InventorsJonathan Mark Bentley, Paul Hebeisen, Sven Taylor
Life of this patent
Estimating the term…
Abstract
Novel compounds of formula (I): wherein X1, X2, X3 and X4, n, R1, R2 and R3 are defined in the specification, and pharmaceutically acceptable salts and prodrugs of the compounds of formula (I) have therapeutic uses. These compounds are useful for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea. They are particularly useful for the treatment of obesity.
Claims31
An aza-indolyl derivative selected from the group consisting of a compound of formula (I):
- wherein
- n is 1,2 or 3;
- X1 is nitrogen or CR4;
- X2 is nitrogen or CR5;
- X3 is nitrogen or CR6;
- X4 is nitrogen or CR7;
- wherein one or two of X1, X2, X3 and X4 are nitrogen;
- R1, R2 and R3 are independently selected from hydrogen and alkyl;
- R4, R5, R6 and R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfonyl, alkylsulfoxyl, arylsulfonyl, arylsulfoxyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, and
- wherein for each of X1, X2, X3 and X4 which is nitrogen, adjacent ring atoms selected from the group consisting of X1, X2, X3 and X4 are not substituted by halogen;
- and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.